Propriedades Terapêuticas do Canabidiol em pacientes com Alzheimer
Nenhuma Miniatura disponível
Data
2023-12
Tipo de documento
Artigo Científico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Modalidade de acesso
Acesso aberto
Editora
Autores
CASTRO, Franciele Ferreira
Orientador
QUATRIN, Priscilla Maciel
Coorientador
Resumo
O uso de Canabidiol (CBD) no Brasil é regulamentado pela Agência Nacional de Vigilância Sanitária (ANVISA) por meio da Resolução da Diretoria Colegiada (RDC)
nº 327/2019. Essa regulamentação permite o registro de produtos à base de Cannabis, incluindo o CBD, para uso medicinal, desde que atendam a critérios
rigorosos de qualidade e segurança. Para obter autorização para o uso de CBD, os pacientes devem possuir uma prescrição médica e adquirir o produto em farmácias
autorizadas. A concentração de THC (Delta-9-Tetrahidrocanabinol), o composto psicoativo da Cannabis, é estritamente controlada nos produtos à base de CBD, a fim
de prevenir o uso recreativo da substância. As regulamentações relacionadas ao CBD no Brasil podem estar sujeitas a mudanças à medida que a pesquisa avança e a
compreensão dos benefícios terapêuticos da Cannabis aumenta. O uso de CBD representa uma opção terapêutica promissora para pacientes que buscam
tratamentos alternativos, especialmente para condições médicas que podem se beneficiar do CBD. No entanto, é essencial que o uso do CBD seja supervisionado
por um médico e esteja em conformidade com as regulamentações locais para garantir sua eficácia e segurança.
The use of Cannabidiol (CBD) in Brazil is regulated by the National Health Surveillance Agency (ANVISA) through Resolution of the Collegiate Board (RDC) No. 327/2019. This regulation allows for the registration of Cannabis-based products, including CBD, for medicinal use, provided they meet strict criteria for quality and safety. To obtain authorization for the use of CBD, patients must have a medical prescription and acquire the product from authorized pharmacies. The concentration of THC (tetrahydrocannabinol), the psychoactive compound in Cannabis, is strictly controlled in CBD-based products to prevent recreational use of the substance. Regulations related to CBD in Brazil may be subject to changes as research progresses and understanding of the therapeutic benefits of Cannabis grows. The use of CBD represents a promising therapeutic option for patients seeking alternative treatments, especially for medical conditions that may benefit from CBD. However, it is essential for CBD use to be supervised by a physician and comply with local regulations to ensure its effectiveness and safety.
The use of Cannabidiol (CBD) in Brazil is regulated by the National Health Surveillance Agency (ANVISA) through Resolution of the Collegiate Board (RDC) No. 327/2019. This regulation allows for the registration of Cannabis-based products, including CBD, for medicinal use, provided they meet strict criteria for quality and safety. To obtain authorization for the use of CBD, patients must have a medical prescription and acquire the product from authorized pharmacies. The concentration of THC (tetrahydrocannabinol), the psychoactive compound in Cannabis, is strictly controlled in CBD-based products to prevent recreational use of the substance. Regulations related to CBD in Brazil may be subject to changes as research progresses and understanding of the therapeutic benefits of Cannabis grows. The use of CBD represents a promising therapeutic option for patients seeking alternative treatments, especially for medical conditions that may benefit from CBD. However, it is essential for CBD use to be supervised by a physician and comply with local regulations to ensure its effectiveness and safety.
Palavras-chave
Alzhaimer, Canabidiol, Terapêuticas, propriedades, benefícios